Analysis of matched tumor and ctDNA during anti-EGFR targeted treatment uncovered mechanisms of secondary resistance to EGFR blockade and concluded that liquid biopsies could be a more robust alternative to tissue to track the genomic evolution of advanced CRC [78]. The gene discussed is EGFR; the disease is colorectal carcinoma.